Englumafusp alfa

Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells[1].

Product Specifications

CAS Number

[2417199-08-5]

Product Name Alternative

CD19-4-1BBL; RO7227166; RG6076

UNSPSC

12352203

Target

CD19

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/englumafusp-alfa.html

Purity

99.93

Solubility

10 mM in DMSO

Smiles

[Englumafuspalfa]

Molecular Weight

(179.19 kDa)

References & Citations

[1]Antonio Tapia-Galisteo, et al. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023 Jul 27;16 (1) :83.|[2]George Fromm, et al. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front Immunol. 2023 Sep 19:14:1236332.